0000899243-21-039857.txt : 20211012 0000899243-21-039857.hdr.sgml : 20211012 20211012163047 ACCESSION NUMBER: 0000899243-21-039857 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211008 FILED AS OF DATE: 20211012 DATE AS OF CHANGE: 20211012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mainolfi Nello CENTRAL INDEX KEY: 0001821189 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 211318882 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS, SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-08 0 0001815442 Kymera Therapeutics, Inc. KYMR 0001821189 Mainolfi Nello C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 1 1 0 0 Chief Executive Officer Common Stock 2021-10-08 4 M 0 41544 2.08 A 505743 D Common Stock 2021-10-08 4 S 0 21236 55.5598 D 484507 D Common Stock 2021-10-08 4 S 0 9369 56.8247 D 475138 D Common Stock 2021-10-08 4 S 0 2078 57.2887 D 473060 D Common Stock 2021-10-08 4 S 0 7920 59.2756 D 465140 D Common Stock 2021-10-08 4 S 0 670 60.3165 D 464470 D Common Stock 2021-10-08 4 S 0 271 61.87 D 464199 D Common Stock 2021-10-11 4 M 0 6456 2.08 A 470655 D Common Stock 2021-10-11 4 S 0 5712 53.5791 D 464943 D Common Stock 2021-10-11 4 S 0 744 54.4979 D 464199 D Stock Option (Right to Buy) 2.08 2021-10-08 4 M 0 41544 0.00 D 2029-11-13 Common Stock 41544 35181 D Stock Option (Right to Buy) 2.08 2021-10-11 4 M 0 6456 0.00 D 2029-11-13 Common Stock 6456 28725 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.10 to $56.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.19 to $57.185. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.20 to $58.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.90 to $59.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.91 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.19 to $54.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.28 to $54.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. /s/ Bruce Jacobs, as Attorney-in-Fact 2021-10-12